The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the ...

Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Orionis to receive $105 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for the discovery of small-molecule monovale ...

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...